OrthoNovis has received U.S. Food and Drug Administration (FDA) clearance for its BPS wrist fracture system.

The clearance allows the company to market its line of locking wrist plates that are indicated for the fixation of simple and complex intra- articular and extra-articular fractures, and for osteotomies of the distal radius in adults. Specifically, the device is indicated for fixation of Fractures AO types A2, A3, B1, B3, C1, C2, and C3.

The system isn’t intended for spinal use.

The BPS wrist fracture system features titanium distal radius plates, two hole-six hole, and standard width. It features variable angle locking screw technology, as well.

“This milestone will allow OrthoNovis to compete in the rapidly growing US orthopedic fracture fixation market,” said Ken West, OrthoNovis’ president and CEO. “Our BPS Wrist Fracture System is a critical step in the build-out of our complete line of orthopedic implants featuring our patented technologies and financially responsible pricing. We are well positioned to grow and will be releasing several new product lines that will address the treatment and fixation of commonly performed Orthopaedic procedures.”

OrthoNovis focuses on widely used, market proven products used to treat common fractures and bone osteotomies. The resulting products incorporate patented and clinically advanced features. The company said they are priced significantly less than its competition.